Olfactory nerve

The tantalising scent of rain or freshly baked bread: why can certain smells transport us back in time?

Retrieved on: 
Wednesday, September 27, 2023

Simply by living among sawdust and woodchips, you learn to distinguish the different smells of wood.

Key Points: 
  • Simply by living among sawdust and woodchips, you learn to distinguish the different smells of wood.
  • Years after my father retired, I was walking through the underbelly of a hospital when, completely by chance, I stumbled upon the maintenance room.
  • Suddenly and unexpectedly, I was transported back to my native Toledo (in Spain), to my father’s carpentry workshop.

Smells that revive past emotions

    • The scent of freshly baked cakes or bread, the chlorine of a swimming pool in summer, a salty sea breeze, coffee, and rain are smells that cause our minds to recover memories and emotions that we thought long forgotten.
    • Memory is the brain’s ability to compile, store and recover information based on past experiences.
    • Numerous scientific studies have tried to discover how we can recover memories and sensations from the past through a particular smell.

A direct line to emotional memory

    • For this reason, a familiar smell activates the same areas of the brain as those related to emotional memory.
    • In fact, scent induced memories tend to be connected to past experiences with a greater emotional significance than other senses.

The loss of smell, a sign of neurological illness

    • Many of us experienced this first hand during the covid-19 pandemic, when millions of people lost their sense of smell.
    • Intriguingly, many disorders linked to a loss of smell are neurodegenerative, where one of the associated symptoms is memory loss.
    • LH, this reads as though all loss of smell ends up with Alzheimer’s, which i don’t think is what is meant, given the next paragraph.

Olfactory gymnastics to rehabilitate your memory?

    • Consequently, in recent years there has been interest in determining the therapeutic potential of scents to stimulate and rehabilitate memory in patients with neurological disorders.
    • Olfactory enrichment –smelling a range of different scents– can reverse loss of smell caused by an infection, craneal trauma, Parkinson’s and aging.
    • Obviously, more research is needed to definitively conclude that regular olfactory stimulation helps to protect the brain and prevent cognitive decline or impairment.

Virpax Pharmaceuticals Reports 2022 Year-End Results

Retrieved on: 
Wednesday, March 22, 2023

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2022, and other recent developments.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2022, and other recent developments.
  • On December 8, 2022, Virpax received Pre-Investigational New Drug (PIND) application guidance from the FDA for NobrXiol.
  • FINANCIAL RESULTS FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021
    Twelve Months Ended December 31, 2022
    General and administrative expenses increased by $3,896,078, or 54%, to $11,082,463 for the year ended December 31, 2022, from $7,186,385 for the year ended December 31, 2021.
  • At December 31, 2022, Virpax had cash of approximately $19.0 million.

Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote

Retrieved on: 
Thursday, January 12, 2023

Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote.

Key Points: 
  • Las Vegas Nevada, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the launch of a concept phase to develop an intra-nasal field-deliverable nerve agent antidote.
  • Nerve agents kill brain cells leading to respiratory failure, seizures, and death within minutes of exposure.
  • Previous work in humans completed by Odyssey has shown that intranasal administration of spray-dried powders leads to low plasma concentrations compared to an intravenous route.
  • Oximes are an antidote for organophosphate nerve agents however the current application is through a skin auto-injector.

Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324)

Retrieved on: 
Wednesday, January 4, 2023

Their involvement with this program is expected to include advising on trial design, regulatory pathway development and patient recruitment.

Key Points: 
  • Their involvement with this program is expected to include advising on trial design, regulatory pathway development and patient recruitment.
  • Additionally, it is anticipated that they will support Virpax with patient advocacy groups and grant applications.
  • He is a recognized authority in drug development with an expertise in anti-epileptic drugs, pain, and abuse-deterrent opioids.
  • Dr. Lawrence Fried is an experienced clinical leader in epilepsy and neurology and a practicing epileptologist.

Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324)

Retrieved on: 
Wednesday, December 14, 2022

Virpax now has guidance on how to proceed with the IND enabling studies and possible regulatory pathways to pursue for NobrXiol, stated Dr. Sheila A. Mathias, Chief Scientific Officer for Virpax.

Key Points: 
  • Virpax now has guidance on how to proceed with the IND enabling studies and possible regulatory pathways to pursue for NobrXiol, stated Dr. Sheila A. Mathias, Chief Scientific Officer for Virpax.
  • This is a significant step forward for the NobrXiol project and we are very pleased with the outcome of the pre-IND meeting with the FDA, said Anthony P. Mack, Chairman and CEO of Virpax.
  • Virpax is developing branded product candidates for non-addictive pain management and neurological disorders using its proprietary technologies that optimize and target drug delivery.
  • Virpax is initially seeking FDA approval of its three different patented drug delivery platforms.

Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases

Retrieved on: 
Tuesday, October 11, 2022

Key Points: 
  • Las Vegas, Nevada, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, announces the formation of Odyssey Neuropharma, Inc., a wholly owned subsidiary, focused on developing drugs to treat neurological disorders.
  • Many drugs have failed in neuroscience research due to the inability to jump the hurdle that is the BBB.
  • This targeted approach requires less drug to accomplish neuroprotection further reducing drug levels in the plasma which minimizes side effects.
  • Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions.

Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device

Retrieved on: 
Tuesday, October 19, 2021

Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, today announced the filing of a provisional patent on its novel nasal drug delivery device.

Key Points: 
  • Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, today announced the filing of a provisional patent on its novel nasal drug delivery device.
  • This novel breath-propelled nasal device gives Odyssey that opportunity.
  • Odyssey is interested in bringing other neurological drugs into our portfolio that can also benefit from this nasal device specialization, commented Michael Redmond, CEO of Odyssey Group International.
  • Odyssey Group International, Inc. (OTC: ODYY ) is a technology company with a focus in the area of life saving medical solutions.

Noveome Biotherapeutics, Inc. to Present at the 10th Annual Traumatic Brain Injury Conference (Virtual), November 2-4, 2020

Retrieved on: 
Tuesday, November 3, 2020

Dr. Brown will discuss the development of Noveomes neuroprotective program which is evaluating intranasal nose-to-brain delivery of its novel platform biologic, ST266, to treat traumatic brain injury and optic nerve/retinal diseases and injuries.

Key Points: 
  • Dr. Brown will discuss the development of Noveomes neuroprotective program which is evaluating intranasal nose-to-brain delivery of its novel platform biologic, ST266, to treat traumatic brain injury and optic nerve/retinal diseases and injuries.
  • AMP cells are produced by culturing a select population of amnion-derived epithelial cells under proprietary conditions.
  • Noveome has demonstrated successful intranasal delivery of this secretome to the brain via the olfactory nerves.
  • Topline data from Noveomes Phase 1 open-label clinical trial in Glaucoma Suspect patients are expected in the fourth quarter of 2020.

Human Coronaviruses May Target Neurons

Retrieved on: 
Wednesday, April 22, 2020

LAVAL, QC, April 22 2020 /CNW Telbec/ -The family of human coronaviruses and other respiratory viruses may be capable of infecting the central nervous system.

Key Points: 
  • LAVAL, QC, April 22 2020 /CNW Telbec/ -The family of human coronaviruses and other respiratory viruses may be capable of infecting the central nervous system.
  • "Our research on the neuroinvasive and neuropathogenic capacities of human coronaviruses suggests that they can reach the smell centre of the brain, primarily via the olfactory nerve," says the researcher, who has been studying coronaviruses for nearly 40 years.
  • Unlike most neurons in the brain, olfactory neurons can regenerate.
  • From the odour-sensitive neurons in the nasal cavity, the infection could potentially spread to the neurons in the smell centre via direct communication.